Phase 1 imaging study of GH001 in patients with treatment-resistant depression

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Aug 2022 According to a GH Research media release, the company has received positive outcome of pre-IND meeting with USFDA and expects to submit the IND for GH001 in TRD not later than the first quarter of 2023.
31 Mar 2022 New trial record
28 Mar 2022 According to a GH Research media release, the company has recently submitted a request for a pre-IND meeting with the FDA to discuss planned filing of a U.S. IND for GH001 in TRD and meeting has been granted by the FDA for the second quarter of 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com